ClinicalTrials.gg
RecruitingNCT05881863Updated Jan 7, 2026

To Investigate Airway Oxygen Concentrations During Rigid Bronchoscopy Procedures Performed With High Frequency Jet Ventilation

An observational study in Central Airway Obstruction, sponsored by University of Minnesota. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-07.

Sponsored by University of Minnesota · Observational

How we know

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
50
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 40 studies in Airway Obstruction with a site in United States — 8 open to participants now, 9 under way, none of them phase 3. Airway Obstruction · United States.

Planned enrollment
9th of 11
50 · median 168
Started
2024
with 3 others
Observational
11 of 40
2 open now
Registered
31st of 40
by date

Among the 40 studies in Airway Obstruction with a site in United States, this one is the 9th largest by planned enrollment of the 11 observational ones that give a count, is one of 4 that started in 2024, is one of 11 observational ones, and was the 31st registered.

Airway Obstruction

148 studies on the registry are indexed under Airway Obstruction; 26 are open to participants now.

Browse Airway Obstruction studies →

Open to participants now

8 of the 40 studies in Airway Obstruction with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 20 Airway Obstruction studies recruiting now, 13 (65%) set no upper age limit and 5 (25%) stop at 75 or younger; 3 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Airway Obstruction with a site in United States, or all of them as a file.
02

Study summary

Thermal ablation (use of treatment modalities that generate heat) has become a widely used tool for treatment of central airway obstruction (e.g. laser, electrocautery, radiofrequency, and argon plasma coagulation). However, this method carries with it an increased risk for airway fire - a surgical fire that occurs in a patient's airway and could also include a fire in the attached breathing circuit. To decrease the risk of airway fire during mechanical ventilation with an endotracheal tube, the concentration of inspired oxygen (FiO2) is set below 40% while waiting for end tidal oxygen concentration (EtO2) to fall below 40% prior to starting thermal ablation. There is no published literature describing O2 concentration within the airways (AiO2) during jet ventilation with rigid bronchoscopy. The co-investigators of this study have recently collected data on AiO2 during rigid bronchoscopy using manual low frequency jet ventilation/high frequency jet ventilation with a period of apnea. The intent of this study is to measure the time taken for the central airway oxygen concentration to drop from 90 to 40% when the "laser mode" is activated on the Monsoon jet ventilator. Ventilation is continued during "laser mode."

03

Conditions studied

  • Central Airway Obstruction

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients undergoing rigid bronchoscopy for treatment of central airway obstruction at FV UMMC will be identified.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients undergoing rigid bronchoscopy for treatment of central airway obstruction at FV UMMC will be identified.
  • 18 years or older
  • Need rigid bronchoscopy as pre-determined by the interventional pulmonologist

Exclusion criteria

Exclusion Criteria:

  • Refusal to sign consent
  • Pregnant patients
  • Hemodynamic instability defined as continuous infusion of medication in order to support blood pressure and/or heart rate/rhythm
  • Respiratory instability defined as SpO2\<90% with >90% supplemental oxygen.
  • Ineligible for rigid bronchoscopic intubation
  • Latex allergy
  • Evidence of fistulous airway
  • Active Bronchopleural fistula
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No

Interventions

  • OtherNo intervention

    This is an observational study

06

What researchers measure

Primary outcomes

  1. Time in seconds to AiO2 from 90 to 40%

    Time in seconds to AiO2 from 90 to 40% after activating laser mode on the monsoon jet ventilator.

    Time frame: baseline

Secondary outcomes

  1. Differences in time to laser mode AiO2

    Differences in time to laser mode AiO2 between trachea and left and right mainstem bronchi.

    Time frame: baseline

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Dec 2026, 35 months after the start.

Of 28 observational studies under Airway Obstruction, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 28. This study's planned 35 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2023
First posted
May 31, 2023
StartActual
Jan 12, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Jan 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05881863
Responsible party
Sponsor
First posted
May 31, 2023
Start date
Jan 12, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jan 7, 2026

Study contacts

Candace Nelson
Contact
nelso377@umn.edu
Sudarshan Setty, MD
principal investigator · University of Minnesota

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion